Q3 2025 Management View CEO Robert Fried opened by highlighting "another record performance with $34 million in revenue, a 33 ...

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has ...

Niagen Bioscience (NAGE) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.02 per share a year ago. These ...

Niagen Bioscience Inc (NAGE) reports a 33% revenue increase and forms a new strategic partnership, despite challenges from ...

Niagen Bioscience (NAGE) has approved a share repurchase program under which the company is authorized to repurchase up to $10M of outstanding common stock over ...

The Company’s flagship patented nicotinamide riboside (NR) ingredient, Niagen®, is manufactured, encapsulated, and bottled in the U.S. and is currently classified as exempt from tariffs, minimizing ...

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced it has increased its full-year ...

-- Total net sales increased 37% to $31.1 million, with Tru Niagen(R) sales reaching $22.7 million, growing 22%. -- Niagen(R) ingredient sales increased 135% to $7.4 million including food-grade and ...

Tru Niagen ® Pro 1,000mg is recommended by physicians and used by pro-athletes as it is clinically proven to boost NAD + levels by up to 150% in as little as three weeks LOS ANGELES--(BUSINESS ...

Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced its ...

LOS ANGELES (AP) — LOS ANGELES (AP) — Niagen Bioscience, Inc. (NAGE) on Tuesday reported net income of $4.6 million in its third quarter. On a per-share basis, the Los Angeles-based company said it ...

Outperforming NAD+ IV, Niagen IV (patented nicotinamide riboside or NR) provides superior tolerability, a 75% shorter infusion time, and increases NAD+ 20% higher three hours post-infusion ...